Oxlumo Evrópusambandið - íslenska - EMA (European Medicines Agency)

oxlumo

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - Önnur meltingarvegi og efnaskipti vörur, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Spikevax (previously COVID-19 Vaccine Moderna) Evrópusambandið - íslenska - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Leqvio Evrópusambandið - íslenska - EMA (European Medicines Agency)

leqvio

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipid breytandi lyf - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Skysona Evrópusambandið - íslenska - EMA (European Medicines Agency)

skysona

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - Önnur lyf í taugakerfinu - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Amvuttra Evrópusambandið - íslenska - EMA (European Medicines Agency)

amvuttra

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - Önnur lyf í taugakerfinu - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Lamictal Tuggu-/dreifitafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 50 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 50 mg

Lamictal Tuggu-/dreifitafla 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 5 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 5 mg

Lamictal Tuggu-/dreifitafla 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 25 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 25 mg

Lamictal Tuggu-/dreifitafla 200 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 200 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 200 mg

Lamictal Tuggu-/dreifitafla 2 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 2 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 2 mg